QS Research · Michael Burry's Scion Capital analyst template · 2006
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
As of 2026-11-21 · 12/15 boxes filled from SEC filings and market data
Report price $39.23 (close 2026-11-20)
Conclusion: WATCH
Conviction medium · base case +27% · downside -24% · upside +33%
The market is pricing Teva off its cash engine and brand mix rather than a generic-only profile: the $45.73B enterprise value is 2.65x TTM revenue and 18.9x TTM EBITDA, while free cash flow is $1.24B and the quality score is 34/100. That supports a WATCH label: the base case is not far enough above the current price to justify more conviction, and the EBITDA multiple already sits above the peer set. The base case is $49.88 (+27.1%), built on EV/Sales at 3.37x, the peer median across five peers; the downside is $30.02 (-23.5%), built on -10.0% sales at a compressed EV/Sales of 2.25x (today 2.65x); and the upside is $52.29 (+33.3%), built on a re-rating to 3.37x on the cited dated catalyst. Those cases bracket a balanced setup, with the base requiring the peer median multiple rather than a re-rating beyond it. The reverse DCF still prices +10.3% annual revenue growth for 10 years, against +4.3% in the latest fiscal year, so the market is already assuming a meaningful acceleration.
Key numbers
- Share price: $39.23
- Market cap: $45.77B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $17.23B
- EV / EBITDA (TTM): 18.9x
- P/E (TTM): 90.5x
- FCF yield: 2.7%
- Price / book: 5.74x
- Earnings-quality flags (TTM): Restructuring charges -$150.0M (30% of net income); Debt extinguishment -$224.0M (44% of net income); Income tax benefit on a pre-tax profit (e.g. a valuation allowance release), against a 21% charge $212.0M (42% of net income)
- P/E, adjusted (TTM): 68.5x
- P/E, operating (tax-normalized) (TTM): 111.6x
- EV / FCF (TTM): 37.0x
- Revenue growth (latest fiscal year): +4.3%
- ROIC (TTM): 13.6%
- WACC: 8.0%
- Economic profit spread: +5.7 pts
The 15 boxes
- ✓ 1. Long-form business notes
Teva is a three-segment generics-plus-innovative biopharmaceutical maker (United States, Europe, International Markets) with ~34,000 employees in 57 markets, a US distribution arm (Anda), and a manufacturing base of 33 finished-dosage plants in 21 countries. Between the FY2020 10-K and the FY2025 10-K the language and portfolio shifted from 'specialty medicines' and 500+ US generics to 'innovative medicines' and 350+ US generics, with manufacturing and product pruning, the March 2025 Japan venture divestiture, and a May 2023 'Pivot to Growth' plan targeting ~$700M of net savings through 2027. On the XBRL facts I have (all post the 2016 acquisition period), revenue ran $16.66B (FY2020) down to a $14.93B trough (FY2022) and back to $17.26B (FY2025) with $17.23B TTM to Sep 2026, while GAAP operating income swung between -$3.57B (FY2020) and +$2.16B (FY2025). Operating cash flow was steadier than earnings: $1.22B-$1.77B every year, with capex of roughly $0.5B.
- ✓ 2. Competitive advantage
The filings describe a low-pricing-power business, not a moat-protected one: generics were $9,421M, or 55% of FY2025 revenue, and the company states generic medicines are 'generally less profitable' with price erosion in each segment. Scale shows up in Europe (pan-European footprint) and International Markets, but not in pricing, and operating income swung from -$3.57B (FY2020) to $2.16B (FY2025) with $1.44B on the TTM to 2026-09-30. The only durable line is cash generation, $1.22B-$1.77B of operating cash flow every year from FY2020 to the TTM, and cost cuts (headcount 37,851 at 2023-12-31 to 33,950 at 2025-12-31) are the main lever offered against price erosion.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue was $4,395 million, down 2% year over year, as U.S. generic products fell 39% on lenalidomide competition while AUSTEDO, AJOVY and UZEDY grew. Gross margin expanded and non-GAAP operating income rose, but GAAP operating income fell on higher legal settlements and impairments. The earnings release raised FY2026 revenue and brand outlooks, and the 10-Q reported no material risk-factor changes from the FY2025 10-K. Q3 operating cash flow fell to $241 million, while free cash flow was $495 million.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.